# Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients

Study · id `cardio:ct-nct03385538` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03385538](<https://clinicaltrials.gov/study/NCT03385538>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03385538

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT03385538. Allocation not applicable; no masking; primary purpose prevention. Start 2015-11-01 (actual); primary completion 2017-07-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT03385538, source copy `cardio:ctgov-nct03385538-2017-12-28`, retrieved 2026-10-26)
- Started: 2015-11-01 (actual) (ClinicalTrials.gov record NCT03385538, source copy `cardio:ctgov-nct03385538-2017-12-28`, retrieved 2026-10-26)
- Primary completion: 2017-07-30 (actual) (ClinicalTrials.gov record NCT03385538, source copy `cardio:ctgov-nct03385538-2017-12-28`, retrieved 2026-10-26)
- Completion: 2017-07-30 (actual) (ClinicalTrials.gov record NCT03385538, source copy `cardio:ctgov-nct03385538-2017-12-28`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT03385538, source copy `cardio:ctgov-nct03385538-2017-12-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03385538-2017-12-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
- Acronym: CLOGIS
- Condition: Ischemic Stroke
- Intervention (Drug): Clopidogrel
- Lead sponsor: Zealand University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Zealand University Hospital (`cardio:org-zealand-university-hospital`)

## Provenance

Content hash: 024ac1ca031a9b7b78e061811558ed3d17a0aa0d64b6db1d8b121b85e79c36d6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
